Alvotech secures financing facilities of approximately $136 million

Reykjavik, iceland , nov. 16, 2022 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financing facilities securing gross proceeds of approximately $136 million, at current exchange rates. "these financing facilities are designed to provide flexibility and additional resources for advancing the company's growing biosimilar pipeline,” said joel morales, chief financial officer of alvotech.
ALVO Ratings Summary
ALVO Quant Ranking